COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,010 Articles (22,627 medRxiv, 8,383 bioRxiv)

Most recent first Previous |  Page 1058: Articles 10571-10580  | Next

Deep Mutational Engineering of broadly-neutralizing and picomolar affinity nanobodies to accommodate SARS-CoV-1 & 2 antigenic polymorphism
Laroche, A., Orsini Delgado, M. L., Cuniasse, P., Dubois, S., Sierocki, R., Gallais, F., Debroas, S., Bellanger, L., Simon, S., Maillere, B., Nozach, H.
10.1101/2021.12.07.471597 — Posted: 2021-12-09
Orally administered epeleuton inhibits SARS-CoV-2 viral load, replication and pathology in the Syrian Hamster model
Climax, J., Hamza, M., Lafferty, A., Guilfoyle, K., van Amerongen, G., Stadler, K., Wohlsein, P., Baumgärtner, W., Weissbach, M., Coughlan, D.
10.1101/2021.12.07.471588 — Posted: 2021-12-09
Combinatorial mRNA vaccination enhances protection against SARS-CoV-2 delta variant
Hajnik, R. L., Plante, J. A., Liang, Y., Alameh, M.-G., Tang, J., Zhong, C., Adam, A., Scharton, D., Rafael, G. H., Liu, Y., Hazell, N. C., Sun, J., Soong, L., Shi, P.-Y., Wang, T., Sun, J., Weissman, D., Weaver, S. C., Plante, K. S., Hu, H.
10.1101/2021.12.08.471664 — Posted: 2021-12-09
B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes
Cao, Y. R., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., Wang, J., Wang, Y., Niu, X., Yang, S., Liang, H., Sun, H., Li, T., Yu, Y., Cui, Q., Liu, S., Yang, X., Du, S., Zhang, Z., Hao, X., Shao, F., Jin, R., Wang, X., Xiao, J., Wang, Y., Xie, X. S.
10.1101/2021.12.07.470392 — Posted: 2021-12-09
Simultaneous analysis of antigen-specific B and T cells after SARS-CoV-2 infection and vaccination
Newell, K. L., Waldran, M. J., Thomas, S. J., Endy, T. P., Waickman, A. T.
10.1101/2021.12.08.471684 — Posted: 2021-12-09
Predictive profiling of SARS-CoV-2 variants by deep mutational learning
Taft, J. M., Weber, C. R., Gao, B., Ehling, R. A., Han, J., Frei, L., Metcalfe, S. W., Yermanos, A., Kelton, W., Reddy, S. T.
10.1101/2021.12.07.471580 — Posted: 2021-12-09
Plant-based expression of SARS-CoV-2 antigens for use in an oral vaccine
Power, M., Azad, T., Bell, J. C., MacLean, A.
10.1101/2021.12.07.471131 — Posted: 2021-12-09
Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals
Redd, A., Nardin, A., Kared, H., Bloch, E. M., Abel, B., Pekosz, A., Laeyendecker, O., Fehlings, M., Quinn, T., Tobian, A. A.
10.1101/2021.12.06.471446 — Posted: 2021-12-09
A descriptive analysis of 2020 California Occupational Safety and Health Administration COVID-19-related complaints
Thomas, M. D., Matthay, E. C., Duchowny, K. A., Riley, A. R., Khela, H., Chen, Y.-H. C., Bibbins-Domingo, K., Glymour, M. M.
10.1101/2021.12.06.21262384 — Posted: 2021-12-09
Opening up safely: public health system requirements for ongoing COVID-19 management based on evaluation of Australia's surveillance system performance
Lokuge, K., D'Onise, K., Banks, E., Street, T., Jantos, S., Baptista, M., Glass, K.
10.1101/2021.12.06.21266926 — Posted: 2021-12-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).